190.11
1.04 (0.55%)
| Previous Close | 189.07 |
| Open | 188.60 |
| Volume | 166,836 |
| Avg. Volume (3M) | 194,698 |
| Market Cap | 3,741,691,904 |
| Price / Earnings (TTM) | 84.12 |
| Price / Earnings (Forward) | 22.88 |
| Price / Sales | 14.75 |
| Price / Book | 3.94 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -73.07% |
| Operating Margin (TTM) | -80.87% |
| Diluted EPS (TTM) | -7.29 |
| Quarterly Revenue Growth (YOY) | 46.30% |
| Total Debt/Equity (MRQ) | 0.56% |
| Current Ratio (MRQ) | 5.27 |
| Operating Cash Flow (TTM) | 52.87 M |
| Levered Free Cash Flow (TTM) | 63.35 M |
| Return on Assets (TTM) | -1.14% |
| Return on Equity (TTM) | -16.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Ligand Pharmaceuticals Incorpor | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.75 |
|
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.35% |
| % Held by Institutions | 100.00% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Chicago Capital, Llc | 30 Sep 2025 | 568,611 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 270.00 (Citigroup, 42.02%) | Buy |
| Median | 233.00 (22.56%) | |
| Low | 220.00 (Benchmark, 15.72%) | Buy |
| Average | 239.33 (25.89%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 192.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 10 Dec 2025 | 235.00 (23.61%) | Buy | 184.03 |
| 10 Nov 2025 | 234.00 (23.09%) | Buy | 209.29 | |
| Stifel | 10 Dec 2025 | 230.00 (20.98%) | Buy | 184.03 |
| Citigroup | 09 Dec 2025 | 270.00 (42.02%) | Buy | 185.83 |
| Benchmark | 07 Nov 2025 | 220.00 (15.72%) | Buy | 202.48 |
| HC Wainwright & Co. | 06 Nov 2025 | 231.00 (21.51%) | Buy | 208.22 |
| Oppenheimer | 03 Nov 2025 | 250.00 (31.50%) | Buy | 191.24 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Dec 2025 | Announcement | Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance |
| 06 Nov 2025 | Announcement | Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance |
| 30 Oct 2025 | Announcement | Ligand to Participate in November Investor Conferences |
| 23 Oct 2025 | Announcement | Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 |
| 16 Oct 2025 | Announcement | Ligand to Host Investor Day on December 9, 2025 |
| 09 Oct 2025 | Announcement | Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |